Developmental Therapeutics Program

One Dose Mean Graph

NSC: 764873 / 1	Conc: 1.00E-5 Molar	Test Date: May 07, 2012
Experiment ID: 1205OS68		Report Date: Oct 12, 2012

Panel/Cell Line	Growth Percent
Leukemia	
CCRF-CEM	84.97
HL-60(TB)	56.59
K-562	35.33
MOLT-4	62.89
RPMI-8226	56.68
Non-Small Cell Lung Cancer	
A549/ATCC	73.05
HOP-62	97.00
HOP-92	70.99
NCI-H226	88.63
NCI-H23	71.03
NCI-H322M	87.51
NCI-H460	101.19
NCI-H522	76.55
Colon Cancer	
COLO 205	99.50
HCC-2998	82.63
HCT-116	78.85
HCT-15	79.49
HT29	91.50
KM12	80.53
SW-620	94.01
CNS Cancer	
SF-268	98.23
SF-295	65.36
SF-539	96.84
SNB-19	97.81
SNB-75	83.13
U251	93.71
Melanoma	
LOX IMVI	85.03
MALME-3M	81.00
M14	89.50
MDA-MB-435	44.49
SK-MEL-2	73.33
SK-MEL-28	105.39
SK-MEL-5	58.87
UACC-257	76.65
UACC-62	61.22
Ovarian Cancer	
IGROV1	82.64
OVCAR-3	90.46
OVCAR-4	82.15
OVCAR-5	94.01
OVCAR-8	87.02
NCI/ADR-RES	72.97
SK-OV-3	96.32
Renal Cancer	
786-0	87.61
A498	125.14
ACHN	86.78
CAKI-1	66.52
RXF 393	95.01
SN12C	81.64
TK-10	85.08
UO-31	68.28
Prostate Cancer	
PC-3	62.17
DU-145	109.65
Breast Cancer	
MCF7	92.32
MDA-MB-231/ATCC	82.45
HS 578T	96.97
BT-549	85.11
T-47D	64.50
MDA-MB-468	52.62
Mean	81.50
Delta	46.17
Range	89.81

Mean Growth Percent - Growth Percent